Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
820 stopped studies mapped to Malignant Colorectal Neoplasm and descendants · 90% state a reason
Over the 820 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03148093 | The CHOICE Registry | — | terminated | May 10, 2017 | Taiho Oncology, Inc. | Competing clinical trials and slower than expected patient enrollment | Enrollment / accrual |
| NCT03594448 | Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients | — | terminated | Jul 20, 2018 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT05223673 | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus…(COLSTAR) | Phase 3 | terminated | Feb 4, 2022 | Institut de Recherches Internationales Servier | Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not… | Sponsor / business decision |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT03866239 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in… | Phase 1 | terminated | Mar 7, 2019 | Hoffmann-La Roche | The Sponsor terminated the study because development of cibisatamab has been discontinued. | Other (stated, no rule matched) |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy… | Early Phase 1 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | withdrawn | Other (stated, no rule matched) |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT04231526 | Pembrolizumab in Early Stage Colon Cancer | Phase 2 | withdrawn | Jan 18, 2020 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT05039944 | SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of… | Phase 2 | terminated | Sep 10, 2021 | Sichuan Baili Pharmaceutical Co., Ltd. | Company research strategy adjustment | Sponsor / business decision |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | Phase 2 | terminated | May 16, 2013 | Columbia University | Poor enrollment | Enrollment / accrual |
| NCT05690035 | Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer | Phase 2 | withdrawn | Jan 19, 2023 | Sun Yat-sen University | Due to slow patient recruiting. No patients were enrolled 12 months after study initiation. | Enrollment / accrual |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History… | Phase 2 | terminated | Aug 15, 2018 | John Hays | Sponsor decision | Sponsor / business decision |
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | Phase 2 | terminated | Oct 20, 2015 | Wake Forest University Health Sciences | Funder terminated. | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05609656 | Electroporation and Immunotherapy in Metastatic Colorectal Cancer(ELI) | Phase 2 | terminated | Nov 8, 2022 | Ismail Gögenur | The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included… | Safety / toxicity |
| NCT03730948 | DC Vaccine in Colorectal Cancer | Phase 1 | terminated | Nov 5, 2018 | University of Pennsylvania | Lack of enrollment | Enrollment / accrual |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | N/A | terminated | Jan 22, 2021 | Centre Hospitalier Henri Duffaut - Avignon | Heart rate measurement error | Other (stated, no rule matched) |
| NCT04073615 | A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) | Phase 1 | terminated | Aug 29, 2019 | Elevar Therapeutics | Phase 2 portion of the study was not performed due to redirection of the rivoceranib development… | Other (stated, no rule matched) |
| NCT05648006 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | Phase 2 | terminated | Dec 13, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With… | Phase 2 | withdrawn | Jun 12, 2023 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT00838578 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | Phase 1 / Phase 2 | terminated | Feb 6, 2009 | Kyowa Kirin Co., Ltd. | Per protocol, the study was terminated based on interim analysis results | Efficacy / futility |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid…(MYCure) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Peptomyc S.L. | Phase 1completed; sponsor decided to change strategy to a combination study | Sponsor / business decision |
| NCT03402477 | "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal…(NORWAIT) | — | terminated | Jan 18, 2018 | Helse Stavanger HF | Suspicion of adverse events | Safety / toxicity |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | N/A | terminated | Feb 1, 2021 | Milton S. Hershey Medical Center | Difficulty enrolling and we lost exercise specialist | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05356585 | Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal… | — | withdrawn | May 2, 2022 | Case Comprehensive Cancer Center | Sponsor already published research that was to be obtained from this study. | Other (stated, no rule matched) |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT05310565 | The Effects of Chiropractic in Adults With Colon Cancer(CCX) | N/A | withdrawn | Apr 5, 2022 | Life University | Low recruitment rate | Enrollment / accrual |
| NCT01904968 | Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis | — | withdrawn | Jul 22, 2013 | Centre Hospitalier Universitaire Dijon | not stated | Not stated |
| NCT03733197 | #CuttingCRC: Barbershop-Based Trial & Colorectal Cancer | N/A | withdrawn | Nov 7, 2018 | Medical College of Wisconsin | PI no longer employed at institutuion | Other (stated, no rule matched) |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant…(P2RX7) | N/A | terminated | Nov 18, 2014 | Centre Hospitalier Universitaire de Nice | the tissue mass of each biopsy sample was not sufficient to perform an exploratory analysis to… | Other (stated, no rule matched) |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human… | Phase 2 | terminated | Nov 21, 2019 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
| NCT04518449 | Medial Border of Laparoscopic D3 Lymphadenectomy for Right Colon Cancer | — | withdrawn | Aug 19, 2020 | Shanghai Minimally Invasive Surgery Center | no funds | Funding |
| NCT04274790 | Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer(FLUORIB) | — | withdrawn | Feb 18, 2020 | Centre Leon Berard | Lack of funding | Funding |
| NCT04812743 | Colorectal Health Research Champions | N/A | terminated | Mar 24, 2021 | Virginia Commonwealth University | End of grant funding | Funding |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | Phase 1 / Phase 2 | terminated | May 24, 2012 | Gilead Sciences | not stated | Not stated |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT03500874 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | Phase 3 | terminated | Apr 18, 2018 | Sun Yat-sen University | The study was terminated prematurely due to FUDR production halt in China | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT03806244 | Feasibility of Stereotactic Navigation in Laparoscopic Surgery for Colorectal Cancer(PELVINAV) | N/A | terminated | Jan 16, 2019 | IHU Strasbourg | Departure of the two main investigators | Other (stated, no rule matched) |
| NCT04379830 | Preoperative Very Low Energy Diet for Obese Rectal Cancer Patients | N/A | withdrawn | May 8, 2020 | McMaster University | There were no patients recruited during the trial period. This was a result of: 1) COVID-19… | COVID-19 / pandemic |
| NCT03135652 | Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or… | Phase 2 | withdrawn | May 1, 2017 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Inadequate patient enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 4, 2024source: clinicaltrials